Use of Antimalarials in Dermatology
Authors:
R. Litvik 1,2
Authors place of work:
Kožní oddělení Fakultní nemocnice Ostrava
přednosta prim. MUDr. Yvetta Vantuchová, Ph. D.
1; Centrum plastické chirurgie a chirurgie ruky Fakultní nemocnice Ostrava
přednosta prim. MUDr. Martin Paciorek
2
Published in the journal:
Čes-slov Derm, 92, 2017, No. 2, p. 55-61
Category:
Reviews (Continuing Medical Education)
Summary
The author gives an overview of current knowledge regarding the use of antimalarials in dermatology. Common antimalarial drugs include chloroquine, hydroxychloroquine and quinacrine. Antimalarials, mainly chloroquine and hydroxychloroquine, have been used in dermatology for more than 50 years in the treament of cutaneous lupus erythematosus. Mechanism of their action is broad, currently they are known as lysosomotropic drugs. Treatment with antimalarials is safe, ocular toxicity should be mainly considered.
Key words:
antimalarial – chloroquine – hydroxychloroquine – lupus erythematosus
Zdroje
1. ASCH, P. H., CAUSSADE, P., MARQUART-ELBAZ, C. et al. Chloroquine-induced achromotrichia. Ann Dermatol Venereol, 1997, 124, p. 552–556.
2. BAGUET, J. P., TREMEL, F., FABRE, M. Cloroquine cardiomyopathy with conduction disorders. Heart, 1999, 81, p. 221–223.
3. BONDESON, J., SUNDLER, R. Antimalarial drugs inhibit phospholipase A2 activation and induction of interleukin 1beta and tumor necrosis factor alpha in macrophages: implications for their mode of action in rheumatoid arthritis. Gen Pharmacol, 1998, 30, p. 356–366.
4. BUCHANAN, N., TOUBI, E., KHAMASHTA, M. et al. Hydrochloroquine and lupus pregnancy: review of series of 36 cases. Ann Rheum Dis, 1996, 55, p. 486–488.
5. CAHN, M., LEVY, E., SHAFFER, B. Polymorphous light eruption, the effect of chloroquine phosphate in modifying reactions to ultra-violet light. J Invest Dermatol, 1956, 26, p. 201–207.
6. CALLEN, J. P. Chronic cutaneous lupus erythematosus. Arch Dermatol, 1982, 118, p. 412–416.
7. CANNISTRACI, C., LESNONI LA PAROLA, I., FALCHI, M. et al. Treatment of generalized granuloma annulare with hydroxychloroquine. Dermatology, 2005, 211, p. 167–168.
8. COSTEDOAT-CHALUMEAU, N., AMOURA, Z., AYMARD,G. et al. Evidence of transplacental passage of hydroxychloroquine in humans. Arthritis Rheum, 2002, 46, p. 1123–1124.
9. COSTEDOAT-CHALUMEAU, N., AMOURA, Z. et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Arthritis Rheum, 2003, 48, p. 3207–3211.
10. ČELADNÍK, M. et al. Organická chemie. 1. vydání, Avicenum: Praha 1990, s. 539–540.
11. DE DUVE, C., DE BARSY, T., POOLE, B. et al. Lysosomotropic agents. Biochem Pharmacol, 1974, 23, p. 495–531.
12. DUCHARME, J., FARINOTTI, R. Clinical pharmacokinetics and metabolism of chloroquine.
13. DUCHOŇ, J. et al. Lékařská chemie a biochemie. 1. vydání, Avicenum: Praha 1985, s. 345–346.
14. EASTERBROOK, M. An ophtalmological view on the effciacy and safety of chloroquine versus hydroxychloroquine. J Rheumatol, 1999, 26, p. 1866–1868.
15. ERNEST, E., ROSE, M., LEE, R. Modification of transoperative changes in blood fluidity by hydroxychloroquine: a possible explanation for the drug´s antithrombotic effect. Pharmatherapeutica, 1984, 4, p. 48–52.
16. ESPINOLA, R. G., PIERANGELI, S. S., GHARAVI, A. E. et al. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholid antibodies. Thromb Haemost, 2002, 87, p. 518–522.
17. EVANS, R. L., KHALID, S., KINNEY, J. L. Antimalarial psychosis revisited. Arch Dermatol, 1984, 120, p. 765–767.
18. FADRHONCOVÁ, A. Farmakoterapie kožních nemocí. 1. vydání, Grada: Praha 1999, s. 208–209.
19. FURNER, B. B. Treatment of subacute cutaneous lupus erythematosus. Int J Dermatol, 1990, 29, p. 542–547.
20. HODIS, H., QUISMORIO, F. J., WICKHAM, E. et al. The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. J Rheumatol, 1993, 20, p. 661–665.
21. Chasset, F., Frances, C., Barete, S. et al. Influence of smoking on the efficacy of antimalarials in cutaneous lupus: A meta-analysis of the literature. J Am Acad Dermatol, 72, 2015, p. 634–639.
22. JAREMKO, W. M.,BEUTNER, E. H., KUMAR, V. et al. Chronic ulcerative stomatitis associated with a specific immunologic marker. J Am Acad Dermatol, 1990, 22, p. 215–220.
23. JONES, E., CALLEN, J. P. Hydrochloroquine is effective therapy for control of cutaneous sarcoidal granulomas. J Am Acad Dermatol, 1990, 23, p. 487–489.
24. JOVER, J. A., LEON, L., PATO, E. et al. Long-term use of antimalarial drugs in rheumatoic diseases. Clin Exp Rheumatol, 2012, 30, p. 380–387.
25. KALIA, S., DUTZ, J. P. New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther, 2007, 20, p. 160–174.
26. KAUFMANN, A. M., KRISE, J. P. Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications. J Pharm Sci, 2007, 96, p. 729–746.
27. KREUTER, A.,GAIFULLINA, R., TIGGES, C. et al. Lupus erythematosus tumidus. Arch Dermatol, 2009, 145, p. 244–248.
28. KRISHNA, S., WHITE, N. J. Pharmacocinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clin Pharmacokinet, 1996, 30, p. 263–299.
29. LESTER, R. S., BURNHAM, T. K., FINE, G. et al. Immunologic concepts of light reactions in lupus erythematosus and polymorphous light eruptions. Arch Dermatol, 1967, 96, p. 1–10.
30. MARMOR, M. F., KELLNER, U., LAI, T. Y. et al. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophtalmology, 2011, 118, p. 415–422.
31. MARMOR, M. F., CARR, R. E., EASTERBROOK, M. et al. American Academy of Ophtalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy, Ophtalmology, 2002, 109, p. 1377–1382.
32. MOK, C., MAK, A., MA, K. Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus. Lupus, 2005, 14, p. 106–112.
33. NGUYEN, T. Q., CAPRA, J. D., SINTHEIMER, R. D. 4-aminoquinoline antimalarials enhance UV-B induced c-jun transcriptional activation. Lupus, 1998, 7, p. 148–153.
34. NOSÁL, R., JANCINOVA, V., PETRIKOVA, M. Chloroquine inhibits stimulated platelets at the arachidonic acid pathway. Thromb Res, 1995, 77, p. 531–542.
35. OCHSENDORF, F. R. Use of antimalarials in dermatology. J Dtsch Dermatol Ges, 2010, 8, p. 829–844.
36. PAGE, F. Treatment of lupus erythematosus with mepacrine. Lancet, 1951, 2, p. 755–758.
37. PARKE, A., WEST, B. Hydrochloroquine in pregnant patients with systemic lupus erythematosus. J Rheumatol, 1996, 23, p. 1715–1718.
38. PENN, S. K., KAO, A. H., SCHOTT, L. L. et al. Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol, 2010, 37, p. 1136–1142.
39. PETRI, M. Hydrochloroquine use in the Baltimore Lupus Cohort: effects on lipid, glucose and thrombosis. Lupus, 1996, 5, p. 516–522.
40. QUAIN, R. D., WERTH, V. P. Management of cutaneous dermatomyositis. Am J Clin Dermatol, 2006, 7, p. 341–351.
41. REKEDAL, L. R., MASSAROTTI, E., GARG, R. et al. Changes in glycosylated hemoglobin after initiation of hydrochloroquine or methotrexate treatment in diabetes patients with rheumatic diseases. Arthritis Rheum, 2010, 62, p. 3569–3573.
42. RODRIGUEZ-CARUNCHO, C., BIELSA MARSOL, I. Antimalarials in Dermatology. Actas Dermosifiliogr, 2014, 105, p. 243–252.
43. RYNES, R. I. Antimalarial drugs in the treatment of rheumatological diseases. Br J Rheumatol, 1997, 36, p. 799–805.
44. SACHET, J., BORBA, E., BONFA, E. et al. Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients. Lupus, 2007, 16, p. 273–278.
45. SHAFFER, B., CAHN, M., LEVY, E. Sarcoidosis apparently cured by quinacrine hydrochloride. Arch Dermatol, 1953, 67, p. 640–641.
46. SJÖLIN-FORSBERG, G., BERNE, B., BLIXT, C. et al. Chloroquine phosphate: a long-term follow-up of drug concentration in skin suction blister fluid and plasma. Acta Derm Venereol, 1993, 73, p. 426–429.
47. Šedová, L., Štolfa J., Horák, P. et al. Doporučení České revmatologické společnosti pro monitorování bezpečnosti léčby revmatoidní artritidy. Čes. Revmatol., 17, 2009, p. 4–15.
48. ŠTORK, J. et al. Dermatovenerologie. 1. vydání, Galén/Karolinum Praha 2008, 502 s.
49. TOMKO, J. et al. Farmakognózia. Osveta: Martin 1999, s. 354–355.
50. TSAKONAS, E., JOSEPH, L., ESDAILE, J. M. et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study group. Lupus, 1998, 7, p. 80–85.
51. VAN BEEK, M. J., PIETTE, W. W. Antimalarials. Dermatol Clin. 2001, 19, p. 147–160.
52. WAHIE, S., DALY, A. K., CORDELL, H. J. et al. Clinical and pharmacogenetic influences on responce to hydroxychloroquine in discoid lupus erythematosus. J Invest Dermatol, 2011, 131, p. 1981–1986.
53. WALLACE, D. J. The history of antimalarials. Lupus, 1996, 5, p. S2–3.
54. WARD, W. Q., WALTER-RYAN, W. G., SHEHI, G. M. Toxic psychosis: a complication of antimalarial therapy. J Am Acad Dermatol, 1985, 12, p. 863–865.
55. WINOCOUR, P. D., KINLOUGH-RATHBONE, R. L.,MUSTARD, J. F. The effect of phospholipase inhibitor mepacrine on platelet aggregation, the platelet release reaction and fibrinogen binding to the platelet surface. Thromb Haemost, 1981, 45, p. 257–262.
56. WOLF, R., WOLF, D., RUOCCO, V. Antimalarials: unapproved uses or indications. Clin dermatol, 2000, 18, p. 17–35.
57. WOO, T. Y., CALLEN, J. P., VOORHEES, J. J. et al. Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol, 1984, 10, p. 592–600.
58. WOZNIACKA, A., McCAULIFFE, D. P. Optimal use of antimalarials in treating cutaneous lupus erythematosus. Am J Clin Dermatol, 2005, 6, p. 1–11.
Štítky
Dermatology & STDs Paediatric dermatology & STDsČlánok vyšiel v časopise
Czech-Slovak Dermatology
2017 Číslo 2
Najčítanejšie v tomto čísle